Tg Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
TG Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.
NASDAQ
TG Therapeutics has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.
NASDAQ
DEF: TG Therapeutics Seeks Stockholder Approval for Incentive Plan Amendment to Boost Share Issuance
TG Therapeutics is asking stockholders to approve an amendment to its 2022 Incentive Plan, increasing the number of shares authorized for issuance from 17,000,000 to 22,000,000.
NASDAQ
TG Therapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
TG Therapeutics is asking stockholders to approve amendments to its Certificate of Incorporation to increase authorized common stock and to its 2022 Incentive Plan to remove the full-value awards limit at the upcoming Annual Meeting on June 14, 2024.